The beginning of the end for Type I diabetes: A new view from immunotherapy science

Jean Van Rampelbergh PhD, VP Clinical & Regulatory at Imcyse SA, introduces ImotopesTM a cutting-edge immunotherapy science with an excellent safety profile that could cure Type 1 diabetes or drastically change treatment options.

Liège, Belgium, January 08, 2021 – More info here

 

CONTACT

Imcyse S.A.
Denis Bedoret
Chief Executive Officer
Mail: contact@imcyse.com 

FOR MEDIA INQUIRES: 
MC Services AG
Anne Hennecke / Brittney Sojeva
Mail: imcyse@mc-services.eu 
Tel.: +49 (0) 211-529-252-14